CLINICAL TRIAL / CIRB17-1739

CTLA 4 Ig (Abatacept) FOR PREVENTION OF ABNORMAL GLUCOSE TOLERANCE AND DIABETES IN RELATIVES AT RISK FOR TYPE 1 DIABETES MELLITUS (Protocol TN 18)